To illustrate the clinical importance of our findings, we evaluated MHC-I expression in a patient who presented with an epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma that subsequently transformed to SCLC following treatment with the EGFR inhibitor Erlotinib (Figure 6E). The gene discussed is EGFR; the disease is small cell lung carcinoma.